12:27 PM EDT, 05/08/2024 (MT Newswires) -- Avidity Biosciences ( RNA ) said Wednesday it has received breakthrough therapy designation from the US Food and Drug Administration for delpacibart etedesiran for the treatment of myotonic dystrophy type 1, a disorder that primarily affects skeletal and cardiac muscle.

The drugmaker said it will begin a global phase 3 study for delpacibart etedesiran this quarter.

Shares of the company were up 1.1% in recent trading.

Price: 25.67, Change: +0.28, Percent Change: +1.10